TRUP Form 144/A — 30,369 Shares Proposed Sale; Recent 19,631-Share Sale
Rhea-AI Filing Summary
Trupanion insider sale notice: This Form 144/A reports a proposed sale of 30,369 shares of Trupanion common stock via Fidelity Brokerage Services (245 Summer Street, Boston, MA) with an aggregate market value of $1,357,943.00. The shares are listed as to be sold approximately on 09/04/2025 on NASDAQ. The filing lists the acquisition history for these shares showing multiple stock awards and one stock option from Trupanion dated between 2018 and 2025, with amounts for each award. The filing also discloses a sale during the past three months: Darryl Rawlings (c/o Trupanion) sold 19,631 shares on 09/03/2025 for gross proceeds of $878,487.25. The filer certifies no undisclosed material adverse information.
Positive
- None.
Negative
- Proposed insider sale of 30,369 Trupanion common shares reported in Form 144/A
- Recent executed sale: Darryl Rawlings sold 19,631 shares on 09/03/2025 for $878,487.25
- Concentration of shares originates from multiple compensation stock awards and one option issued by Trupanion between 2018 and 2025
Insights
TL;DR: Routine insider notice of proposed stock sale; lists award history and a recent executed sale.
The Form 144/A documents a proposed disposition of 30,369 Trupanion common shares through a broker on NASDAQ with an indicated aggregate market value of $1,357,943.00 and includes a detailed acquisition schedule showing multiple compensation-related stock awards and one stock option granted by the company from 2018 through 2025. The filing additionally reports a sale executed on 09/03/2025 by Darryl Rawlings of 19,631 shares for $878,487.25. This notice is procedural under Rule 144 and supplies transparency about timing and provenance of the shares; it does not provide operational or earnings data.
TL;DR: Insider compliance disclosure; provides provenance of shares and confirms no undisclosed material information.
The submission appears to be a compliance filing to satisfy Rule 144 prerequisites for an insider sale, enumerating the grant dates and quantities for the securities to be sold and affirming the signer is not aware of undisclosed material adverse information. The record of a recent sale (9/3/2025) is included, which helps stakeholders track insider liquidity events. The form contains no discussion of executive role changes, trading plans, or other governance actions.